10x Genomics, Inc. (TXG)Healthcare | Health Information Services | Pleasanton, United States | NasdaqGS
61.54 USD
-3.31
(-5.104%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 61.54 |
Hot Take ↕ | Aug. 22, 2026, 3:21 a.m. EDT
The investment case for 10x Genomics is currently broken by a severe deterioration in business fundamentals. The company is posting negative revenue growth (-12.7%) alongside widening losses, resulting in a catastrophic 87% decline in share price over the last five years. This multi-year structural decline, capped by two consecutive years of falling prices, signals that the market has lost faith in the company's ability to execute or scale. Despite a technically strong recent bounce off the lows, the underlying reality is a failing growth story with no dividend support and a balance sheet that cannot offset the operational drag. The options market confirms this pessimism, with traders stacking heavy protection against further drops. Until the revenue trajectory turns positive and profitability is restored, this remains a high-risk speculative vehicle rather than a viable investment. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.226997 |
| AutoTheta | 0.338978 |
| MSTL | 0.343481 |
| AutoETS | 0.349727 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 8.03 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.758 |
| Excess Kurtosis | -0.45 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 9.545 |
| Revenue per Share | 4.832 |
| Market Cap | 8,018,118,656 |
| Forward P/E | 302.66 |
| Beta | 2.04 |
| Profit Margins | -12.18% |
| Website | https://www.10xgenomics.com |
As of Aug. 22, 2026, 3:21 a.m. EDT: Speculators are aggressively betting on a crash, with massive open interest in deep out-of-the-money puts (strikes as low as $5 and $25) compared to negligible call volume. While there is some activity in near-term calls around the current price, the overwhelming positioning suggests a fear of a significant downside move rather than a bullish breakout.
| Attribute | Value |
|---|---|
| 52 Week Change | 3.8504114 |
| Address1 | 6,230 Stoneridge Mall Road |
| All Time High | 208.99 |
| All Time Low | 6.78 |
| Ask | 78.11 |
| Ask Size | 1 |
| Audit Risk | 3 |
| Average Analyst Rating | 2.3 - Buy |
| Average Daily Volume10 Day | 2,990,870 |
| Average Daily Volume3 Month | 3,270,864 |
| Average Volume | 3,270,864 |
| Average Volume10Days | 2,990,870 |
| Beta | 2.039 |
| Bid | 45.72 |
| Bid Size | 1 |
| Board Risk | 5 |
| Book Value | 6.337 |
| City | Pleasanton |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 61.54 |
| Current Ratio | 5.693 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 65.0 |
| Day Low | 60.82 |
| Debt To Equity | 9.545 |
| Display Name | 10x Genomics |
| Earnings Call Timestamp End | 1,786,046,400 |
| Earnings Call Timestamp Start | 1,786,046,400 |
| Earnings Timestamp | 1,786,046,400 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -41,201,000 |
| Ebitda Margins | -0.06679 |
| Enterprise To Ebitda | -183.124 |
| Enterprise To Revenue | 12.23 |
| Enterprise Value | 7,544,881,664 |
| Eps Current Year | 0.105 |
| Eps Forward | 0.20333 |
| Eps Trailing Twelve Months | -0.59 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 47.4841 |
| Fifty Day Average Change | 14.055901 |
| Fifty Day Average Change Percent | 0.2960128 |
| Fifty Two Week Change Percent | 385.04114 |
| Fifty Two Week High | 66.94 |
| Fifty Two Week High Change | -5.4000015 |
| Fifty Two Week High Change Percent | -0.08066928 |
| Fifty Two Week Low | 11.16 |
| Fifty Two Week Low Change | 50.38 |
| Fifty Two Week Low Change Percent | 4.514337 |
| Fifty Two Week Range | 11.16 - 66.94 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,568,295,000,000 |
| Float Shares | 118,184,513 |
| Forward Eps | 0.20333 |
| Forward P E | 302.6607 |
| Free Cashflow | 179,656,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 1,178 |
| Fullday Change | -3.31 |
| Fullday Change Percent | -5.10408 |
| Fullday Price | 61.54 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.70112 |
| Gross Profits | 432,527,008 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01526 |
| Held Percent Institutions | 1.12005 |
| Implied Shares Outstanding | 130,291,168 |
| Industry | Health Information Services |
| Industry Disp | Health Information Services |
| Industry Key | health-information-services |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | 10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California. |
| Long Name | 10x Genomics, Inc. |
| Market | us_market |
| Market Cap | 8,018,118,656 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_223288117 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -75,125,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 8,449,382,244 |
| Number Of Analyst Opinions | 13 |
| Open | 63.88 |
| Operating Cashflow | 127,085,000 |
| Operating Margins | -0.15198 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 925 401 7300 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 61.54 |
| Post Market Time | 1,787,961,291 |
| Previous Close | 64.85 |
| Price Eps Current Year | 586.0953 |
| Price Hint | 2 |
| Price To Book | 9.71122 |
| Price To Sales Trailing12 Months | 12.997206 |
| Profit Margins | -0.12178001 |
| Quick Ratio | 5.085 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.3125 |
| Region | US |
| Regular Market Change | -3.31 |
| Regular Market Change Percent | -5.10408 |
| Regular Market Day High | 65.0 |
| Regular Market Day Low | 60.82 |
| Regular Market Day Range | 60.82 - 65.0 |
| Regular Market Open | 63.88 |
| Regular Market Previous Close | 64.85 |
| Regular Market Price | 61.54 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 2,360,177 |
| Return On Assets | -0.05049 |
| Return On Equity | -0.09398 |
| Revenue Growth | -0.127 |
| Revenue Per Share | 4.832 |
| Sand P52 Week Change | 0.1966995 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 10 |
| Shares Outstanding | 120,212,296 |
| Shares Percent Shares Out | 0.122200005 |
| Shares Short | 15,927,548 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 16,252,519 |
| Short Name | 10x Genomics, Inc. |
| Short Percent Of Float | 0.17930001 |
| Short Ratio | 4.97 |
| Source Interval | 15 |
| State | CA |
| Symbol | TXG |
| Target High Price | 65.0 |
| Target Low Price | 40.0 |
| Target Mean Price | 49.53846 |
| Target Median Price | 50.0 |
| Total Cash | 552,033,024 |
| Total Cash Per Share | 4.237 |
| Total Debt | 78,796,000 |
| Total Revenue | 616,910,976 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.59 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 27.57275 |
| Two Hundred Day Average Change | 33.96725 |
| Two Hundred Day Average Change Percent | 1.2319138 |
| Type Disp | Equity |
| Volume | 2,360,177 |
| Website | https://www.10xgenomics.com |
| Zip | 94,588-3260 |